Retrointegration2023—Papers from the 7th International Conference on Retroviral Integration

/in

Engelman AN, Grandgenett DP, Maertens GN, Yoder KE, Kvaratskhelia M. Retrointegration2023-Papers from the 7th International Conference on Retroviral Integration. Viruses. 2025 Jun 23;17(7):879. doi: 10.3390/v17070879.

Mucosal boosting increases protective efficacy of an influenza vaccine in mice

/in

Wang L, Chan CN, Chaudhari J, Hope D, Espinosa Perez AA, Lasrado N, Li Z, Waller-Pulido A, Cabrera-Barragan DN, Verrette B, Nangle SJ, Ayala-Bernot J, Jacob-Dolan C, Lifton M, Strutton E, Fisher J, Mbiwan E, Rossler A, Schrag S, Barouch DH. Mucosal boosting increases protective efficacy of an influenza vaccine in mice. iScience. 2025 May 21;28(6):112721. doi: 10.1016/j.isci.2025.112721.

Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study

/in

Huang Y, Zhang L, Gelderblom H, Seaton KE, Yates NL, Paez CA, Karuna ST, Andrew P, Gamble T, Robinson ST, Ledgerwood JE, Hyrien O, Walsh SR, Gay CL, Gwira JA, Spiegel HML, Sobieszczyk ME, Mannheimer SB, Edupuganti S, Hurt CB, Stephenson KE, Yu C, Kelley CF, Mahomed S, Siegel M, Yacovone M, Pensiero MN, Donnell D, Cohen MS, Corey L, Gilbert PB, Koup RA, Tomaras GD; VRC 605, HVTN 127/HPTN 087, HVTN 130/HPTN 089, HVTN 136/HPTN 092, and HVTN 140/HPTN 101 study teams. Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study. EBioMedicine. 2025 Jul;117:105804. doi: 10.1016/j.ebiom.2025.105804. Epub 2025 Jun 13.

The tumor microenvironment’s role in the response to immune checkpoint blockade

/in

Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A, Boussiotis VA. The tumor microenvironment’s role in the response to immune checkpoint blockade. Nature Cancer. 2025 Jun;6(6):924-937. doi: 10.1038/s43018-025-00986-3. Epub 2025 Jun 13.

Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates

/in

Malewana RD, Stalls V, May A, Lu X, Martinez DR, Schäfer A, Li D, Barr M, Sutherland LL, Lee E, Parks R, Beck WE, Newman A, Bock KW, Minai M, Nagata BM, DeMarco CT, Denny TN, Oguin TH 3rd, Rountree W, Wang Y, Mansouri K, Edwards RJ, Smith L, Sempowski GD, Eaton A, Muramatsu H, Henderson R, Tam Y, Barbosa C, Tang J, Cain DW, Santra S, Moore IN, Andersen H, Lewis MG, Golding H, Seder R, Khurana S, Montefiori DC, Pardi N, Weissman D, Baric RS, Acharya P, Haynes BF, Saunders KO. Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates. Science Translation Medicine. 2025 Jun 11;17(802):eadn5651. doi: 10.1126/scitranslmed.adn5651. Epub 2025 Jun 11.

Timed chromatin invasion during mitosis governs prototype foamy virus integration site selection and infectivity

/in

Lagadec F, Singh PK, Calmels C, Lapaillerie D, Lindemann D, Parissi V, Cherepanov P, Engelman AN, Lesbats P. Timed chromatin invasion during mitosis governs prototype foamy virus integration site selection and infectivity. Nucleic Acids Res. 2025 May 22;53(10):gkaf449. doi: 10.1093/nar/gkaf449.

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial

/in

Seaton KE, Paez CA, Yu C, Karuna ST, Gamble T, Miner MD, Heptinstall J, Zhang L, Gao F, Yacovone M, Spiegel H, Dumond JB, Anderson M, Piwowar-Manning E, Dye B, Tindale I, Proulx-Burns L, Trahey M, Takuva S, Takalani A, Bailey VC, Kalams SA, Scott H, Mkhize NN, Weiner JA, Ackerman ME, McElrath MJ, Pensiero M, Barouch DH, Montefiori D, Tomaras GD, Corey L, Cohen MS, Huang Y, Mahomed S, Siegel M, Kelley CF; HVTN 140/HPTN 101 study team. Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial. Lancet HIV. 2025 Jun;12(6):e405-e415. doi: 10.1016/S2352-3018(25)00012-8.

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data

/in

Andrews LIB, Halloran ME, Neuzil KM, van der Laan L, Huang Y, Andriesen J, Patel M, Fisher LH, Janes H, Rouphael N, Walsh SR, Theodore DA, Tieu HV, Sobieszczyk M, El Sahly HM, Baden LR, Falsey AR, Campbell TB, Kelley CF, Healy CM, Immergluck L, Luft B, Hirsch I, de Bruyn G, Truyers C, Priddy F, Sumner KM, Flannery B, Follmann D, Gilbert PB; COVID-19 Prevention Network (CoVPN). Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials. JAMA Netw Open. 2025 May 1;8(5):e2512763. doi: 10.1001/jamanetworkopen.2025.12763

Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design

/in

Dam, K. A., Gristick, H. B., Li, Y. E., Yang, Z., Gnanapragasam, P. N. P., West, A. P., Jr, Seaman, M. S., & Bjorkman, P. J. (2025). Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design. Cell reports, 44(5), 115713. https://doi.org/10.1016/j.celrep.2025.115713

SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells

/in

Sambaturu N, Fray EJ, Hariharan V, Wu F, Zitzmann C, Simonetti FR, Barouch DH, Siliciano JD, Siliciano RF, Ribeiro RM, Perelson AS, Molina-París C, Leitner T. SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells. Cell Reports. 2025 May 27;44(5):115663. doi: 10.1016/j.celrep.2025.115663. Epub 2025 May 5.